Moser M - Search Results

1

Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.

Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J. Bertram U, et al. Among authors: moser m. J Thromb Thrombolysis. 2002 Dec;14(3):197-203. doi: 10.1023/a:1025044625487. J Thromb Thrombolysis. 2002. PMID: 12913399

2

[Antithrombotic prevention and therapy in coronary heart disease].

Bode C, Kohler B, Moser M, Zimmermann R, Strasser RH, Kübler W. Bode C, et al. Among authors: moser m. Internist (Berl). 1997 Jul;38(7):658-66. doi: 10.1007/s001080050077. Internist (Berl). 1997. PMID: 9333599 Review. German. No abstract available.

3

Clinical trial results with a new plasminogen activator.

Bode C, Peter K, Moser M, Smalling RW, Weaver WD. Bode C, et al. Among authors: moser m. Eur Heart J. 1997 Dec;18 Suppl F:F17-21. doi: 10.1093/eurheartj/18.suppl_f.17. Eur Heart J. 1997. PMID: 9447336 Review.

4

Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.

Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C. Peter K, et al. Among authors: moser m. Blood. 1998 Nov 1;92(9):3240-9. Blood. 1998. PMID: 9787160 Free article.

5

Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.

Nordt TK, Moser M, Kohler B, Ruef J, Peter K, Kübler W, Bode C. Nordt TK, et al. Among authors: moser m. Thromb Haemost. 1998 Dec;80(6):881-6. Thromb Haemost. 1998. PMID: 9869154

6

Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18).

Peter K, Schwarz M, Conradt C, Nordt T, Moser M, Kübler W, Bode C. Peter K, et al. Among authors: moser m. Circulation. 1999 Oct 5;100(14):1533-9. doi: 10.1161/01.cir.100.14.1533. Circulation. 1999. PMID: 10510057

7

Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.

Moser M, Nordt T, Peter K, Ruef J, Kohler B, Schmittner M, Smalling R, Kübler W, Bode C. Moser M, et al. Circulation. 1999 Nov 2;100(18):1858-64. doi: 10.1161/01.cir.100.18.1858. Circulation. 1999. PMID: 10545429 Clinical Trial.

8

Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA).

Nordt TK, Moser M, Kohler B, Kübler W, Bode C. Nordt TK, et al. Among authors: moser m. Thromb Haemost. 1999 Sep;82 Suppl 1:121-3. Thromb Haemost. 1999. PMID: 10695501 Review.

9

Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.

Peter K, Kohler B, Straub A, Ruef J, Moser M, Nordt T, Olschewski M, Ohman ME, Kübler W, Bode C. Peter K, et al. Among authors: moser m. Circulation. 2000 Sep 26;102(13):1490-6. doi: 10.1161/01.cir.102.13.1490. Circulation. 2000. PMID: 11004138

10

4-hydroxynonenal induces apoptosis, NF-kappaB-activation and formation of 8-isoprostane in vascular smooth muscle cells.

Ruef J, Moser M, Bode C, Kübler W, Runge MS. Ruef J, et al. Among authors: moser m. Basic Res Cardiol. 2001 Apr;96(2):143-50. doi: 10.1007/s003950170064. Basic Res Cardiol. 2001. PMID: 11327332

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,776 results

Search Page

Filters